nodes	percent_of_prediction	percent_of_DWPC	metapath
Epoprostenol—PTGER1—renal system—kidney cancer	0.00206	0.216	CbGeAlD
Epoprostenol—PTGER1—kidney—kidney cancer	0.002	0.208	CbGeAlD
Epoprostenol—CYP2C9—urine—kidney cancer	0.00186	0.195	CbGeAlD
Epoprostenol—PTGIR—renal system—kidney cancer	0.00128	0.133	CbGeAlD
Epoprostenol—PTGIR—kidney—kidney cancer	0.00123	0.129	CbGeAlD
Epoprostenol—PTGIR—gonad—kidney cancer	0.00114	0.119	CbGeAlD
Epoprostenol—Hypersensitivity—Sunitinib—kidney cancer	0.000413	0.000589	CcSEcCtD
Epoprostenol—Decreased appetite—Vincristine—kidney cancer	0.000412	0.000588	CcSEcCtD
Epoprostenol—Pruritus—Sorafenib—kidney cancer	0.000412	0.000588	CcSEcCtD
Epoprostenol—Vomiting—Erlotinib—kidney cancer	0.000412	0.000587	CcSEcCtD
Epoprostenol—Musculoskeletal discomfort—Gemcitabine—kidney cancer	0.00041	0.000585	CcSEcCtD
Epoprostenol—Gastrointestinal disorder—Vincristine—kidney cancer	0.00041	0.000584	CcSEcCtD
Epoprostenol—Fatigue—Vincristine—kidney cancer	0.000409	0.000583	CcSEcCtD
Epoprostenol—Rash—Erlotinib—kidney cancer	0.000409	0.000582	CcSEcCtD
Epoprostenol—Dermatitis—Erlotinib—kidney cancer	0.000408	0.000582	CcSEcCtD
Epoprostenol—Palpitations—Paclitaxel—kidney cancer	0.000408	0.000582	CcSEcCtD
Epoprostenol—Insomnia—Gemcitabine—kidney cancer	0.000407	0.00058	CcSEcCtD
Epoprostenol—Headache—Erlotinib—kidney cancer	0.000406	0.000579	CcSEcCtD
Epoprostenol—Loss of consciousness—Paclitaxel—kidney cancer	0.000406	0.000579	CcSEcCtD
Epoprostenol—Constipation—Vincristine—kidney cancer	0.000406	0.000578	CcSEcCtD
Epoprostenol—Pain—Vincristine—kidney cancer	0.000406	0.000578	CcSEcCtD
Epoprostenol—Paraesthesia—Gemcitabine—kidney cancer	0.000404	0.000576	CcSEcCtD
Epoprostenol—Cardiac disorder—Capecitabine—kidney cancer	0.000404	0.000576	CcSEcCtD
Epoprostenol—Flushing—Capecitabine—kidney cancer	0.000404	0.000576	CcSEcCtD
Epoprostenol—Cough—Paclitaxel—kidney cancer	0.000403	0.000574	CcSEcCtD
Epoprostenol—Asthenia—Sunitinib—kidney cancer	0.000403	0.000574	CcSEcCtD
Epoprostenol—Dyspnoea—Gemcitabine—kidney cancer	0.000401	0.000572	CcSEcCtD
Epoprostenol—Nausea—Vinblastine—kidney cancer	0.0004	0.000571	CcSEcCtD
Epoprostenol—Somnolence—Gemcitabine—kidney cancer	0.0004	0.00057	CcSEcCtD
Epoprostenol—Nausea—Everolimus—kidney cancer	0.000399	0.000569	CcSEcCtD
Epoprostenol—Diarrhoea—Sorafenib—kidney cancer	0.000399	0.000569	CcSEcCtD
Epoprostenol—Pruritus—Sunitinib—kidney cancer	0.000397	0.000566	CcSEcCtD
Epoprostenol—Angiopathy—Capecitabine—kidney cancer	0.000395	0.000563	CcSEcCtD
Epoprostenol—Arthralgia—Paclitaxel—kidney cancer	0.000393	0.00056	CcSEcCtD
Epoprostenol—Chest pain—Paclitaxel—kidney cancer	0.000393	0.00056	CcSEcCtD
Epoprostenol—Myalgia—Paclitaxel—kidney cancer	0.000393	0.00056	CcSEcCtD
Epoprostenol—Mediastinal disorder—Capecitabine—kidney cancer	0.000392	0.000559	CcSEcCtD
Epoprostenol—Anxiety—Paclitaxel—kidney cancer	0.000392	0.000558	CcSEcCtD
Epoprostenol—Decreased appetite—Gemcitabine—kidney cancer	0.000391	0.000558	CcSEcCtD
Epoprostenol—Hypersensitivity—Dactinomycin—kidney cancer	0.000391	0.000558	CcSEcCtD
Epoprostenol—Chills—Capecitabine—kidney cancer	0.000391	0.000557	CcSEcCtD
Epoprostenol—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—kidney cancer	0.00039	0.000557	CcSEcCtD
Epoprostenol—Gastrointestinal disorder—Gemcitabine—kidney cancer	0.000389	0.000554	CcSEcCtD
Epoprostenol—Fatigue—Gemcitabine—kidney cancer	0.000388	0.000553	CcSEcCtD
Epoprostenol—Gastrointestinal pain—Vincristine—kidney cancer	0.000388	0.000553	CcSEcCtD
Epoprostenol—Dizziness—Sorafenib—kidney cancer	0.000386	0.00055	CcSEcCtD
Epoprostenol—Constipation—Gemcitabine—kidney cancer	0.000385	0.000549	CcSEcCtD
Epoprostenol—Pain—Gemcitabine—kidney cancer	0.000385	0.000549	CcSEcCtD
Epoprostenol—Nausea—Erlotinib—kidney cancer	0.000385	0.000549	CcSEcCtD
Epoprostenol—Dry mouth—Paclitaxel—kidney cancer	0.000384	0.000548	CcSEcCtD
Epoprostenol—Diarrhoea—Sunitinib—kidney cancer	0.000384	0.000547	CcSEcCtD
Epoprostenol—Mental disorder—Capecitabine—kidney cancer	0.000381	0.000544	CcSEcCtD
Epoprostenol—Asthenia—Dactinomycin—kidney cancer	0.000381	0.000543	CcSEcCtD
Epoprostenol—Confusional state—Paclitaxel—kidney cancer	0.00038	0.000542	CcSEcCtD
Epoprostenol—Anaphylactic shock—Paclitaxel—kidney cancer	0.000377	0.000537	CcSEcCtD
Epoprostenol—Oedema—Paclitaxel—kidney cancer	0.000377	0.000537	CcSEcCtD
Epoprostenol—Abdominal pain—Vincristine—kidney cancer	0.000375	0.000535	CcSEcCtD
Epoprostenol—Body temperature increased—Vincristine—kidney cancer	0.000375	0.000535	CcSEcCtD
Epoprostenol—Infection—Paclitaxel—kidney cancer	0.000374	0.000534	CcSEcCtD
Epoprostenol—Flatulence—Capecitabine—kidney cancer	0.000373	0.000532	CcSEcCtD
Epoprostenol—Dizziness—Sunitinib—kidney cancer	0.000371	0.000529	CcSEcCtD
Epoprostenol—Shock—Paclitaxel—kidney cancer	0.000371	0.000529	CcSEcCtD
Epoprostenol—Vomiting—Sorafenib—kidney cancer	0.000371	0.000528	CcSEcCtD
Epoprostenol—Orthostatic hypotension—Doxorubicin—kidney cancer	0.00037	0.000528	CcSEcCtD
Epoprostenol—Nervous system disorder—Paclitaxel—kidney cancer	0.00037	0.000527	CcSEcCtD
Epoprostenol—Thrombocytopenia—Paclitaxel—kidney cancer	0.000369	0.000526	CcSEcCtD
Epoprostenol—Tachycardia—Paclitaxel—kidney cancer	0.000368	0.000524	CcSEcCtD
Epoprostenol—Rash—Sorafenib—kidney cancer	0.000368	0.000524	CcSEcCtD
Epoprostenol—Dermatitis—Sorafenib—kidney cancer	0.000367	0.000524	CcSEcCtD
Epoprostenol—Back pain—Capecitabine—kidney cancer	0.000367	0.000523	CcSEcCtD
Epoprostenol—Skin disorder—Paclitaxel—kidney cancer	0.000366	0.000522	CcSEcCtD
Epoprostenol—Headache—Sorafenib—kidney cancer	0.000365	0.000521	CcSEcCtD
Epoprostenol—Muscle spasms—Capecitabine—kidney cancer	0.000364	0.000519	CcSEcCtD
Epoprostenol—Hyperhidrosis—Paclitaxel—kidney cancer	0.000364	0.000519	CcSEcCtD
Epoprostenol—Diarrhoea—Dactinomycin—kidney cancer	0.000363	0.000518	CcSEcCtD
Epoprostenol—Anorexia—Paclitaxel—kidney cancer	0.000359	0.000512	CcSEcCtD
Epoprostenol—Gastritis—Doxorubicin—kidney cancer	0.000359	0.000512	CcSEcCtD
Epoprostenol—Vomiting—Sunitinib—kidney cancer	0.000357	0.000508	CcSEcCtD
Epoprostenol—Body temperature increased—Gemcitabine—kidney cancer	0.000356	0.000507	CcSEcCtD
Epoprostenol—Tremor—Capecitabine—kidney cancer	0.000355	0.000506	CcSEcCtD
Epoprostenol—Rash—Sunitinib—kidney cancer	0.000354	0.000504	CcSEcCtD
Epoprostenol—Dermatitis—Sunitinib—kidney cancer	0.000353	0.000504	CcSEcCtD
Epoprostenol—Abdominal distension—Doxorubicin—kidney cancer	0.000353	0.000503	CcSEcCtD
Epoprostenol—Hypotension—Paclitaxel—kidney cancer	0.000352	0.000502	CcSEcCtD
Epoprostenol—Headache—Sunitinib—kidney cancer	0.000351	0.000501	CcSEcCtD
Epoprostenol—Anaemia—Capecitabine—kidney cancer	0.00035	0.000499	CcSEcCtD
Epoprostenol—Hypersensitivity—Vincristine—kidney cancer	0.00035	0.000498	CcSEcCtD
Epoprostenol—Nausea—Sorafenib—kidney cancer	0.000346	0.000494	CcSEcCtD
Epoprostenol—Musculoskeletal discomfort—Paclitaxel—kidney cancer	0.000343	0.000489	CcSEcCtD
Epoprostenol—Insomnia—Paclitaxel—kidney cancer	0.000341	0.000486	CcSEcCtD
Epoprostenol—Asthenia—Vincristine—kidney cancer	0.00034	0.000485	CcSEcCtD
Epoprostenol—Syncope—Capecitabine—kidney cancer	0.00034	0.000484	CcSEcCtD
Epoprostenol—Paraesthesia—Paclitaxel—kidney cancer	0.000338	0.000482	CcSEcCtD
Epoprostenol—Vomiting—Dactinomycin—kidney cancer	0.000338	0.000481	CcSEcCtD
Epoprostenol—Dyspnoea—Paclitaxel—kidney cancer	0.000336	0.000479	CcSEcCtD
Epoprostenol—Somnolence—Paclitaxel—kidney cancer	0.000335	0.000478	CcSEcCtD
Epoprostenol—Palpitations—Capecitabine—kidney cancer	0.000335	0.000477	CcSEcCtD
Epoprostenol—Rash—Dactinomycin—kidney cancer	0.000335	0.000477	CcSEcCtD
Epoprostenol—Nausea—Sunitinib—kidney cancer	0.000333	0.000475	CcSEcCtD
Epoprostenol—Loss of consciousness—Capecitabine—kidney cancer	0.000333	0.000475	CcSEcCtD
Epoprostenol—Pancytopenia—Doxorubicin—kidney cancer	0.000333	0.000475	CcSEcCtD
Epoprostenol—Dyspepsia—Paclitaxel—kidney cancer	0.000332	0.000473	CcSEcCtD
Epoprostenol—Cough—Capecitabine—kidney cancer	0.000331	0.000471	CcSEcCtD
Epoprostenol—Decreased appetite—Paclitaxel—kidney cancer	0.000328	0.000467	CcSEcCtD
Epoprostenol—Gastrointestinal disorder—Paclitaxel—kidney cancer	0.000325	0.000464	CcSEcCtD
Epoprostenol—Fatigue—Paclitaxel—kidney cancer	0.000325	0.000463	CcSEcCtD
Epoprostenol—Diarrhoea—Vincristine—kidney cancer	0.000325	0.000463	CcSEcCtD
Epoprostenol—Asthenia—Gemcitabine—kidney cancer	0.000323	0.00046	CcSEcCtD
Epoprostenol—Chest pain—Capecitabine—kidney cancer	0.000323	0.00046	CcSEcCtD
Epoprostenol—Arthralgia—Capecitabine—kidney cancer	0.000323	0.00046	CcSEcCtD
Epoprostenol—Myalgia—Capecitabine—kidney cancer	0.000323	0.00046	CcSEcCtD
Epoprostenol—Pain—Paclitaxel—kidney cancer	0.000322	0.000459	CcSEcCtD
Epoprostenol—Constipation—Paclitaxel—kidney cancer	0.000322	0.000459	CcSEcCtD
Epoprostenol—Anxiety—Capecitabine—kidney cancer	0.000322	0.000458	CcSEcCtD
Epoprostenol—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—kidney cancer	0.00032	0.000457	CcSEcCtD
Epoprostenol—Pruritus—Gemcitabine—kidney cancer	0.000318	0.000454	CcSEcCtD
Epoprostenol—Weight decreased—Doxorubicin—kidney cancer	0.000317	0.000452	CcSEcCtD
Epoprostenol—Dry mouth—Capecitabine—kidney cancer	0.000316	0.00045	CcSEcCtD
Epoprostenol—Nausea—Dactinomycin—kidney cancer	0.000315	0.00045	CcSEcCtD
Epoprostenol—Pneumonia—Doxorubicin—kidney cancer	0.000314	0.000448	CcSEcCtD
Epoprostenol—Dizziness—Vincristine—kidney cancer	0.000314	0.000447	CcSEcCtD
Epoprostenol—Infestation NOS—Doxorubicin—kidney cancer	0.000313	0.000446	CcSEcCtD
Epoprostenol—Infestation—Doxorubicin—kidney cancer	0.000313	0.000446	CcSEcCtD
Epoprostenol—Confusional state—Capecitabine—kidney cancer	0.000312	0.000445	CcSEcCtD
Epoprostenol—Oedema—Capecitabine—kidney cancer	0.000309	0.000441	CcSEcCtD
Epoprostenol—Gastrointestinal pain—Paclitaxel—kidney cancer	0.000308	0.000439	CcSEcCtD
Epoprostenol—Diarrhoea—Gemcitabine—kidney cancer	0.000308	0.000439	CcSEcCtD
Epoprostenol—Infection—Capecitabine—kidney cancer	0.000307	0.000438	CcSEcCtD
Epoprostenol—Shock—Capecitabine—kidney cancer	0.000304	0.000434	CcSEcCtD
Epoprostenol—Urinary tract infection—Doxorubicin—kidney cancer	0.000304	0.000433	CcSEcCtD
Epoprostenol—Nervous system disorder—Capecitabine—kidney cancer	0.000303	0.000432	CcSEcCtD
Epoprostenol—Thrombocytopenia—Capecitabine—kidney cancer	0.000303	0.000432	CcSEcCtD
Epoprostenol—Tachycardia—Capecitabine—kidney cancer	0.000302	0.00043	CcSEcCtD
Epoprostenol—Vomiting—Vincristine—kidney cancer	0.000302	0.00043	CcSEcCtD
Epoprostenol—Skin disorder—Capecitabine—kidney cancer	0.0003	0.000428	CcSEcCtD
Epoprostenol—Sweating—Doxorubicin—kidney cancer	0.0003	0.000427	CcSEcCtD
Epoprostenol—Urticaria—Paclitaxel—kidney cancer	0.000299	0.000427	CcSEcCtD
Epoprostenol—Rash—Vincristine—kidney cancer	0.000299	0.000426	CcSEcCtD
Epoprostenol—Hyperhidrosis—Capecitabine—kidney cancer	0.000299	0.000426	CcSEcCtD
Epoprostenol—Dermatitis—Vincristine—kidney cancer	0.000299	0.000426	CcSEcCtD
Epoprostenol—Haematuria—Doxorubicin—kidney cancer	0.000298	0.000425	CcSEcCtD
Epoprostenol—Body temperature increased—Paclitaxel—kidney cancer	0.000298	0.000425	CcSEcCtD
Epoprostenol—Abdominal pain—Paclitaxel—kidney cancer	0.000298	0.000425	CcSEcCtD
Epoprostenol—Headache—Vincristine—kidney cancer	0.000297	0.000424	CcSEcCtD
Epoprostenol—Epistaxis—Doxorubicin—kidney cancer	0.000295	0.00042	CcSEcCtD
Epoprostenol—Anorexia—Capecitabine—kidney cancer	0.000295	0.00042	CcSEcCtD
Epoprostenol—Sinusitis—Doxorubicin—kidney cancer	0.000293	0.000418	CcSEcCtD
Epoprostenol—Hypotension—Capecitabine—kidney cancer	0.000289	0.000412	CcSEcCtD
Epoprostenol—Vomiting—Gemcitabine—kidney cancer	0.000286	0.000408	CcSEcCtD
Epoprostenol—Bradycardia—Doxorubicin—kidney cancer	0.000286	0.000407	CcSEcCtD
Epoprostenol—Rash—Gemcitabine—kidney cancer	0.000284	0.000405	CcSEcCtD
Epoprostenol—Dermatitis—Gemcitabine—kidney cancer	0.000284	0.000404	CcSEcCtD
Epoprostenol—Haemoglobin—Doxorubicin—kidney cancer	0.000282	0.000402	CcSEcCtD
Epoprostenol—Headache—Gemcitabine—kidney cancer	0.000282	0.000402	CcSEcCtD
Epoprostenol—Nausea—Vincristine—kidney cancer	0.000282	0.000402	CcSEcCtD
Epoprostenol—Musculoskeletal discomfort—Capecitabine—kidney cancer	0.000282	0.000402	CcSEcCtD
Epoprostenol—Rhinitis—Doxorubicin—kidney cancer	0.000281	0.000401	CcSEcCtD
Epoprostenol—Haemorrhage—Doxorubicin—kidney cancer	0.000281	0.0004	CcSEcCtD
Epoprostenol—Insomnia—Capecitabine—kidney cancer	0.00028	0.000399	CcSEcCtD
Epoprostenol—Hypoaesthesia—Doxorubicin—kidney cancer	0.000279	0.000398	CcSEcCtD
Epoprostenol—Pharyngitis—Doxorubicin—kidney cancer	0.000279	0.000397	CcSEcCtD
Epoprostenol—Paraesthesia—Capecitabine—kidney cancer	0.000278	0.000396	CcSEcCtD
Epoprostenol—Hypersensitivity—Paclitaxel—kidney cancer	0.000278	0.000396	CcSEcCtD
Epoprostenol—Oedema peripheral—Doxorubicin—kidney cancer	0.000276	0.000394	CcSEcCtD
Epoprostenol—Connective tissue disorder—Doxorubicin—kidney cancer	0.000276	0.000393	CcSEcCtD
Epoprostenol—Dyspnoea—Capecitabine—kidney cancer	0.000276	0.000393	CcSEcCtD
Epoprostenol—Dyspepsia—Capecitabine—kidney cancer	0.000272	0.000388	CcSEcCtD
Epoprostenol—Asthenia—Paclitaxel—kidney cancer	0.00027	0.000385	CcSEcCtD
Epoprostenol—Decreased appetite—Capecitabine—kidney cancer	0.000269	0.000383	CcSEcCtD
Epoprostenol—Nausea—Gemcitabine—kidney cancer	0.000267	0.000381	CcSEcCtD
Epoprostenol—Gastrointestinal disorder—Capecitabine—kidney cancer	0.000267	0.000381	CcSEcCtD
Epoprostenol—Fatigue—Capecitabine—kidney cancer	0.000267	0.00038	CcSEcCtD
Epoprostenol—Pruritus—Paclitaxel—kidney cancer	0.000267	0.00038	CcSEcCtD
Epoprostenol—Pain—Capecitabine—kidney cancer	0.000264	0.000377	CcSEcCtD
Epoprostenol—Constipation—Capecitabine—kidney cancer	0.000264	0.000377	CcSEcCtD
Epoprostenol—Flushing—Doxorubicin—kidney cancer	0.00026	0.000371	CcSEcCtD
Epoprostenol—Cardiac disorder—Doxorubicin—kidney cancer	0.00026	0.000371	CcSEcCtD
Epoprostenol—Diarrhoea—Paclitaxel—kidney cancer	0.000258	0.000368	CcSEcCtD
Epoprostenol—Angiopathy—Doxorubicin—kidney cancer	0.000255	0.000363	CcSEcCtD
Epoprostenol—Gastrointestinal pain—Capecitabine—kidney cancer	0.000253	0.000361	CcSEcCtD
Epoprostenol—Mediastinal disorder—Doxorubicin—kidney cancer	0.000253	0.000361	CcSEcCtD
Epoprostenol—Chills—Doxorubicin—kidney cancer	0.000252	0.000359	CcSEcCtD
Epoprostenol—Dizziness—Paclitaxel—kidney cancer	0.000249	0.000355	CcSEcCtD
Epoprostenol—Mental disorder—Doxorubicin—kidney cancer	0.000246	0.00035	CcSEcCtD
Epoprostenol—Urticaria—Capecitabine—kidney cancer	0.000246	0.00035	CcSEcCtD
Epoprostenol—Body temperature increased—Capecitabine—kidney cancer	0.000244	0.000349	CcSEcCtD
Epoprostenol—Abdominal pain—Capecitabine—kidney cancer	0.000244	0.000349	CcSEcCtD
Epoprostenol—Flatulence—Doxorubicin—kidney cancer	0.000241	0.000343	CcSEcCtD
Epoprostenol—Tension—Doxorubicin—kidney cancer	0.00024	0.000342	CcSEcCtD
Epoprostenol—Vomiting—Paclitaxel—kidney cancer	0.00024	0.000342	CcSEcCtD
Epoprostenol—Rash—Paclitaxel—kidney cancer	0.000238	0.000339	CcSEcCtD
Epoprostenol—Dermatitis—Paclitaxel—kidney cancer	0.000237	0.000338	CcSEcCtD
Epoprostenol—Nervousness—Doxorubicin—kidney cancer	0.000237	0.000338	CcSEcCtD
Epoprostenol—Back pain—Doxorubicin—kidney cancer	0.000236	0.000337	CcSEcCtD
Epoprostenol—Headache—Paclitaxel—kidney cancer	0.000236	0.000337	CcSEcCtD
Epoprostenol—Muscle spasms—Doxorubicin—kidney cancer	0.000235	0.000335	CcSEcCtD
Epoprostenol—Hypersensitivity—Capecitabine—kidney cancer	0.000228	0.000325	CcSEcCtD
Epoprostenol—Anaemia—Doxorubicin—kidney cancer	0.000226	0.000322	CcSEcCtD
Epoprostenol—Agitation—Doxorubicin—kidney cancer	0.000224	0.00032	CcSEcCtD
Epoprostenol—Nausea—Paclitaxel—kidney cancer	0.000224	0.000319	CcSEcCtD
Epoprostenol—Asthenia—Capecitabine—kidney cancer	0.000222	0.000316	CcSEcCtD
Epoprostenol—Syncope—Doxorubicin—kidney cancer	0.000219	0.000312	CcSEcCtD
Epoprostenol—Pruritus—Capecitabine—kidney cancer	0.000219	0.000312	CcSEcCtD
Epoprostenol—Palpitations—Doxorubicin—kidney cancer	0.000216	0.000308	CcSEcCtD
Epoprostenol—Loss of consciousness—Doxorubicin—kidney cancer	0.000215	0.000306	CcSEcCtD
Epoprostenol—Cough—Doxorubicin—kidney cancer	0.000213	0.000304	CcSEcCtD
Epoprostenol—Diarrhoea—Capecitabine—kidney cancer	0.000212	0.000302	CcSEcCtD
Epoprostenol—Chest pain—Doxorubicin—kidney cancer	0.000208	0.000296	CcSEcCtD
Epoprostenol—Arthralgia—Doxorubicin—kidney cancer	0.000208	0.000296	CcSEcCtD
Epoprostenol—Myalgia—Doxorubicin—kidney cancer	0.000208	0.000296	CcSEcCtD
Epoprostenol—Anxiety—Doxorubicin—kidney cancer	0.000207	0.000295	CcSEcCtD
Epoprostenol—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—kidney cancer	0.000207	0.000294	CcSEcCtD
Epoprostenol—Dizziness—Capecitabine—kidney cancer	0.000205	0.000292	CcSEcCtD
Epoprostenol—P2RY12—Platelet activation, signaling and aggregation—PIK3CA—kidney cancer	0.000204	0.000705	CbGpPWpGaD
Epoprostenol—Dry mouth—Doxorubicin—kidney cancer	0.000203	0.00029	CcSEcCtD
Epoprostenol—PTGIS—Metabolism—SLC2A1—kidney cancer	0.000201	0.000697	CbGpPWpGaD
Epoprostenol—Confusional state—Doxorubicin—kidney cancer	0.000201	0.000287	CcSEcCtD
Epoprostenol—Anaphylactic shock—Doxorubicin—kidney cancer	0.000199	0.000284	CcSEcCtD
Epoprostenol—Oedema—Doxorubicin—kidney cancer	0.000199	0.000284	CcSEcCtD
Epoprostenol—Infection—Doxorubicin—kidney cancer	0.000198	0.000282	CcSEcCtD
Epoprostenol—Vomiting—Capecitabine—kidney cancer	0.000197	0.00028	CcSEcCtD
Epoprostenol—Shock—Doxorubicin—kidney cancer	0.000196	0.00028	CcSEcCtD
Epoprostenol—Nervous system disorder—Doxorubicin—kidney cancer	0.000196	0.000279	CcSEcCtD
Epoprostenol—PTGIS—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	0.000195	0.000676	CbGpPWpGaD
Epoprostenol—Thrombocytopenia—Doxorubicin—kidney cancer	0.000195	0.000278	CcSEcCtD
Epoprostenol—Rash—Capecitabine—kidney cancer	0.000195	0.000278	CcSEcCtD
Epoprostenol—Dermatitis—Capecitabine—kidney cancer	0.000195	0.000278	CcSEcCtD
Epoprostenol—Tachycardia—Doxorubicin—kidney cancer	0.000195	0.000277	CcSEcCtD
Epoprostenol—PTGIS—Disease—CDKN2B—kidney cancer	0.000194	0.000672	CbGpPWpGaD
Epoprostenol—CYP2C9—Phase 1 - Functionalization of compounds—POMC—kidney cancer	0.000194	0.000672	CbGpPWpGaD
Epoprostenol—Headache—Capecitabine—kidney cancer	0.000194	0.000276	CcSEcCtD
Epoprostenol—Skin disorder—Doxorubicin—kidney cancer	0.000194	0.000276	CcSEcCtD
Epoprostenol—Hyperhidrosis—Doxorubicin—kidney cancer	0.000193	0.000275	CcSEcCtD
Epoprostenol—PTGER1—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—kidney cancer	0.000192	0.000663	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—CASP2—kidney cancer	0.000191	0.000662	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—CASP2—kidney cancer	0.000191	0.000662	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—AKAP13—kidney cancer	0.000191	0.000662	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—AKAP13—kidney cancer	0.000191	0.000662	CbGpPWpGaD
Epoprostenol—Anorexia—Doxorubicin—kidney cancer	0.00019	0.000271	CcSEcCtD
Epoprostenol—P2RY12—Signaling Pathways—GRB7—kidney cancer	0.00019	0.000658	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—GLIPR1—kidney cancer	0.000189	0.000655	CbGpPWpGaD
Epoprostenol—Hypotension—Doxorubicin—kidney cancer	0.000186	0.000266	CcSEcCtD
Epoprostenol—Nausea—Capecitabine—kidney cancer	0.000184	0.000262	CcSEcCtD
Epoprostenol—Musculoskeletal discomfort—Doxorubicin—kidney cancer	0.000182	0.000259	CcSEcCtD
Epoprostenol—Insomnia—Doxorubicin—kidney cancer	0.00018	0.000257	CcSEcCtD
Epoprostenol—Paraesthesia—Doxorubicin—kidney cancer	0.000179	0.000255	CcSEcCtD
Epoprostenol—Dyspnoea—Doxorubicin—kidney cancer	0.000178	0.000253	CcSEcCtD
Epoprostenol—Somnolence—Doxorubicin—kidney cancer	0.000177	0.000253	CcSEcCtD
Epoprostenol—P2RY12—Signaling Pathways—ITPR2—kidney cancer	0.000177	0.000612	CbGpPWpGaD
Epoprostenol—P2RY12—Hemostasis—RAF1—kidney cancer	0.000176	0.000611	CbGpPWpGaD
Epoprostenol—Dyspepsia—Doxorubicin—kidney cancer	0.000175	0.00025	CcSEcCtD
Epoprostenol—PTGIR—Signaling Pathways—GRB7—kidney cancer	0.000175	0.000605	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—GRB7—kidney cancer	0.000175	0.000605	CbGpPWpGaD
Epoprostenol—Decreased appetite—Doxorubicin—kidney cancer	0.000173	0.000247	CcSEcCtD
Epoprostenol—Gastrointestinal disorder—Doxorubicin—kidney cancer	0.000172	0.000245	CcSEcCtD
Epoprostenol—Fatigue—Doxorubicin—kidney cancer	0.000172	0.000245	CcSEcCtD
Epoprostenol—Pain—Doxorubicin—kidney cancer	0.00017	0.000243	CcSEcCtD
Epoprostenol—Constipation—Doxorubicin—kidney cancer	0.00017	0.000243	CcSEcCtD
Epoprostenol—PTGIS—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	0.00017	0.00059	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—GSTP1—kidney cancer	0.000168	0.000581	CbGpPWpGaD
Epoprostenol—Gastrointestinal pain—Doxorubicin—kidney cancer	0.000163	0.000232	CcSEcCtD
Epoprostenol—PTGER1—Signaling Pathways—ITPR2—kidney cancer	0.000163	0.000563	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—ITPR2—kidney cancer	0.000163	0.000563	CbGpPWpGaD
Epoprostenol—PTGIR—Hemostasis—RAF1—kidney cancer	0.000162	0.000562	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—CTNNA1—kidney cancer	0.00016	0.000554	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—EIF4EBP1—kidney cancer	0.000159	0.000551	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—HSPB1—kidney cancer	0.000159	0.000551	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—ABCB1—kidney cancer	0.000159	0.00055	CbGpPWpGaD
Epoprostenol—CYP2C9—Biological oxidations—GSTP1—kidney cancer	0.000159	0.000549	CbGpPWpGaD
Epoprostenol—Urticaria—Doxorubicin—kidney cancer	0.000158	0.000226	CcSEcCtD
Epoprostenol—P2RY12—Hemostasis—IL2—kidney cancer	0.000158	0.000547	CbGpPWpGaD
Epoprostenol—Body temperature increased—Doxorubicin—kidney cancer	0.000158	0.000225	CcSEcCtD
Epoprostenol—Abdominal pain—Doxorubicin—kidney cancer	0.000158	0.000225	CcSEcCtD
Epoprostenol—CYP2C9—Metapathway biotransformation—GSTP1—kidney cancer	0.000156	0.000542	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—HIF1A—kidney cancer	0.000155	0.000538	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—TSC2—kidney cancer	0.000155	0.000536	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—GSTM1—kidney cancer	0.000154	0.000534	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—ANXA1—kidney cancer	0.000148	0.000512	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—PSMD7—kidney cancer	0.000148	0.000512	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—TSC1—kidney cancer	0.000148	0.000512	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—CTNNA1—kidney cancer	0.000147	0.00051	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—CTNNA1—kidney cancer	0.000147	0.00051	CbGpPWpGaD
Epoprostenol—Hypersensitivity—Doxorubicin—kidney cancer	0.000147	0.000209	CcSEcCtD
Epoprostenol—PTGER1—Signaling Pathways—HSPB1—kidney cancer	0.000147	0.000507	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—EIF4EBP1—kidney cancer	0.000147	0.000507	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—EIF4EBP1—kidney cancer	0.000147	0.000507	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—HSPB1—kidney cancer	0.000147	0.000507	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—CYP1A1—kidney cancer	0.000146	0.000506	CbGpPWpGaD
Epoprostenol—CYP2C9—Biological oxidations—GSTM1—kidney cancer	0.000146	0.000505	CbGpPWpGaD
Epoprostenol—PTGIR—Hemostasis—IL2—kidney cancer	0.000146	0.000504	CbGpPWpGaD
Epoprostenol—CYP2C9—Metapathway biotransformation—GSTM1—kidney cancer	0.000144	0.000498	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—FLT1—kidney cancer	0.000143	0.000496	CbGpPWpGaD
Epoprostenol—Asthenia—Doxorubicin—kidney cancer	0.000143	0.000204	CcSEcCtD
Epoprostenol—Pruritus—Doxorubicin—kidney cancer	0.000141	0.000201	CcSEcCtD
Epoprostenol—CYP2C9—Biological oxidations—CYP1A1—kidney cancer	0.000138	0.000478	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—KIT—kidney cancer	0.000137	0.000474	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—APC—kidney cancer	0.000137	0.000474	CbGpPWpGaD
Epoprostenol—Diarrhoea—Doxorubicin—kidney cancer	0.000136	0.000194	CcSEcCtD
Epoprostenol—CYP2C9—Metapathway biotransformation—CYP1A1—kidney cancer	0.000136	0.000472	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—PSMD7—kidney cancer	0.000136	0.000472	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—ANXA1—kidney cancer	0.000136	0.000472	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—PSMD7—kidney cancer	0.000136	0.000472	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—ANXA1—kidney cancer	0.000136	0.000472	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—TSC1—kidney cancer	0.000136	0.000472	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—TSC1—kidney cancer	0.000136	0.000472	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR downstream signaling—POMC—kidney cancer	0.000135	0.000468	CbGpPWpGaD
Epoprostenol—P2RY12—Hemostasis—VEGFA—kidney cancer	0.000134	0.000465	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—JUNB—kidney cancer	0.000133	0.00046	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—PAK1—kidney cancer	0.000133	0.00046	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—FLT1—kidney cancer	0.000132	0.000457	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—FLT1—kidney cancer	0.000132	0.000457	CbGpPWpGaD
Epoprostenol—Dizziness—Doxorubicin—kidney cancer	0.000132	0.000188	CcSEcCtD
Epoprostenol—PTGIS—Disease—BRAF—kidney cancer	0.000129	0.000445	CbGpPWpGaD
Epoprostenol—P2RY12—Hemostasis—MAPK3—kidney cancer	0.000127	0.00044	CbGpPWpGaD
Epoprostenol—Vomiting—Doxorubicin—kidney cancer	0.000127	0.000181	CcSEcCtD
Epoprostenol—Rash—Doxorubicin—kidney cancer	0.000126	0.000179	CcSEcCtD
Epoprostenol—Dermatitis—Doxorubicin—kidney cancer	0.000126	0.000179	CcSEcCtD
Epoprostenol—Headache—Doxorubicin—kidney cancer	0.000125	0.000178	CcSEcCtD
Epoprostenol—PTGER1—GPCR downstream signaling—POMC—kidney cancer	0.000124	0.000431	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR downstream signaling—POMC—kidney cancer	0.000124	0.000431	CbGpPWpGaD
Epoprostenol—PTGIR—Hemostasis—VEGFA—kidney cancer	0.000124	0.000428	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—POMC—kidney cancer	0.000123	0.000425	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—JUNB—kidney cancer	0.000122	0.000423	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—JUNB—kidney cancer	0.000122	0.000423	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—PAK1—kidney cancer	0.000122	0.000423	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—PAK1—kidney cancer	0.000122	0.000423	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—ACY1—kidney cancer	0.000122	0.000421	CbGpPWpGaD
Epoprostenol—P2RY12—Hemostasis—MAPK1—kidney cancer	0.000121	0.000419	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	0.00012	0.000416	CbGpPWpGaD
Epoprostenol—Nausea—Doxorubicin—kidney cancer	0.000118	0.000169	CcSEcCtD
Epoprostenol—PTGIR—Hemostasis—MAPK3—kidney cancer	0.000117	0.000405	CbGpPWpGaD
Epoprostenol—P2RY12—Hemostasis—KRAS—kidney cancer	0.000114	0.000396	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—POMC—kidney cancer	0.000113	0.000391	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—POMC—kidney cancer	0.000113	0.000391	CbGpPWpGaD
Epoprostenol—PTGIR—Hemostasis—MAPK1—kidney cancer	0.000111	0.000385	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—POMC—kidney cancer	0.000109	0.000378	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—IGF2—kidney cancer	0.000109	0.000376	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—CDKN2B—kidney cancer	0.000108	0.000374	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—RAF1—kidney cancer	0.000107	0.000372	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—ERBB2—kidney cancer	0.000106	0.000368	CbGpPWpGaD
Epoprostenol—PTGIR—Hemostasis—KRAS—kidney cancer	0.000105	0.000364	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—IGF1R—kidney cancer	0.000105	0.000364	CbGpPWpGaD
Epoprostenol—P2RY12—Hemostasis—PIK3CA—kidney cancer	0.000105	0.000363	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—MTOR—kidney cancer	0.000105	0.000363	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—CD4—kidney cancer	0.000105	0.000362	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—PTGS2—kidney cancer	0.000104	0.00036	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—CRABP1—kidney cancer	0.000104	0.000359	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PDHB—kidney cancer	0.000103	0.000358	CbGpPWpGaD
Epoprostenol—CYP2C9—Biological oxidations—POMC—kidney cancer	0.000103	0.000357	CbGpPWpGaD
Epoprostenol—P2RY12—Hemostasis—TP53—kidney cancer	0.000102	0.000352	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—RAF1—kidney cancer	0.000101	0.00035	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—IGF2—kidney cancer	0.0001	0.000346	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—IGF2—kidney cancer	0.0001	0.000346	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR downstream signaling—IL2—kidney cancer	0.0001	0.000346	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—CDKN2B—kidney cancer	9.96e-05	0.000345	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—CDKN2B—kidney cancer	9.96e-05	0.000345	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—CDKN1B—kidney cancer	9.84e-05	0.000341	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—CCBL1—kidney cancer	9.72e-05	0.000336	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—IGF1R—kidney cancer	9.67e-05	0.000335	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—IGF1R—kidney cancer	9.67e-05	0.000335	CbGpPWpGaD
Epoprostenol—PTGIR—Hemostasis—PIK3CA—kidney cancer	9.66e-05	0.000334	CbGpPWpGaD
Epoprostenol—PTGIR—Hemostasis—TP53—kidney cancer	9.35e-05	0.000324	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—RAF1—kidney cancer	9.32e-05	0.000322	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—RAF1—kidney cancer	9.32e-05	0.000322	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—CTNNB1—kidney cancer	9.29e-05	0.000322	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR downstream signaling—IL2—kidney cancer	9.2e-05	0.000318	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR downstream signaling—IL2—kidney cancer	9.2e-05	0.000318	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—IL2—kidney cancer	9.08e-05	0.000314	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—PTEN—kidney cancer	9.06e-05	0.000314	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—ACHE—kidney cancer	8.79e-05	0.000304	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—PTGS2—kidney cancer	8.7e-05	0.000301	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—HIF1A—kidney cancer	8.65e-05	0.000299	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—TSC2—kidney cancer	8.63e-05	0.000299	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PPAT—kidney cancer	8.43e-05	0.000292	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—GLIPR1—kidney cancer	8.43e-05	0.000292	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—IL2—kidney cancer	8.35e-05	0.000289	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—IL2—kidney cancer	8.35e-05	0.000289	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—SCARB1—kidney cancer	8.32e-05	0.000288	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—KDR—kidney cancer	8.27e-05	0.000286	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—PTGS1—kidney cancer	8.24e-05	0.000285	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—HIF1A—kidney cancer	7.96e-05	0.000276	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—HIF1A—kidney cancer	7.96e-05	0.000276	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—TSC2—kidney cancer	7.94e-05	0.000275	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—TSC2—kidney cancer	7.94e-05	0.000275	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—FH—kidney cancer	7.83e-05	0.000271	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—APRT—kidney cancer	7.83e-05	0.000271	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—MAPK3—kidney cancer	7.74e-05	0.000268	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—BCHE—kidney cancer	7.66e-05	0.000265	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—APC—kidney cancer	7.62e-05	0.000264	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—KIT—kidney cancer	7.62e-05	0.000264	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—KDR—kidney cancer	7.61e-05	0.000263	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—KDR—kidney cancer	7.61e-05	0.000263	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—PTEN—kidney cancer	7.59e-05	0.000263	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—MYC—kidney cancer	7.53e-05	0.000261	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—GPC3—kidney cancer	7.37e-05	0.000255	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—MAPK1—kidney cancer	7.36e-05	0.000255	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—MAPK3—kidney cancer	7.3e-05	0.000253	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—POMC—kidney cancer	7.25e-05	0.000251	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—CA2—kidney cancer	7.17e-05	0.000248	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—BRAF—kidney cancer	7.16e-05	0.000248	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—KIT—kidney cancer	7.01e-05	0.000243	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—KIT—kidney cancer	7.01e-05	0.000243	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—APC—kidney cancer	7.01e-05	0.000243	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—APC—kidney cancer	7.01e-05	0.000243	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—ALAD—kidney cancer	6.98e-05	0.000242	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—KRAS—kidney cancer	6.96e-05	0.000241	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—MAPK1—kidney cancer	6.94e-05	0.00024	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—ST3GAL2—kidney cancer	6.82e-05	0.000236	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—MAPK3—kidney cancer	6.72e-05	0.000232	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—MAPK3—kidney cancer	6.72e-05	0.000232	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—POMC—kidney cancer	6.68e-05	0.000231	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—POMC—kidney cancer	6.68e-05	0.000231	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—ALDH1A1—kidney cancer	6.66e-05	0.000231	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR downstream signaling—PIK3CA—kidney cancer	6.63e-05	0.00023	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—BRAF—kidney cancer	6.59e-05	0.000228	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—BRAF—kidney cancer	6.59e-05	0.000228	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—KRAS—kidney cancer	6.56e-05	0.000227	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—PIK3CA—kidney cancer	6.39e-05	0.000221	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—MAPK1—kidney cancer	6.39e-05	0.000221	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—MAPK1—kidney cancer	6.39e-05	0.000221	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PGK1—kidney cancer	6.39e-05	0.000221	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—SLC5A3—kidney cancer	6.39e-05	0.000221	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—LDHB—kidney cancer	6.26e-05	0.000217	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR downstream signaling—PIK3CA—kidney cancer	6.11e-05	0.000211	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR downstream signaling—PIK3CA—kidney cancer	6.11e-05	0.000211	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—KRAS—kidney cancer	6.04e-05	0.000209	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—KRAS—kidney cancer	6.04e-05	0.000209	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—PIK3CA—kidney cancer	6.03e-05	0.000209	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—RAF1—kidney cancer	5.98e-05	0.000207	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—RELA—kidney cancer	5.95e-05	0.000206	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—ERBB2—kidney cancer	5.92e-05	0.000205	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—MTOR—kidney cancer	5.84e-05	0.000202	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—PIK3CA—kidney cancer	5.54e-05	0.000192	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—PIK3CA—kidney cancer	5.54e-05	0.000192	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—RAF1—kidney cancer	5.5e-05	0.000191	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—RAF1—kidney cancer	5.5e-05	0.000191	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—RELA—kidney cancer	5.48e-05	0.00019	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—RELA—kidney cancer	5.48e-05	0.00019	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—CDKN1B—kidney cancer	5.48e-05	0.00019	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—ERBB2—kidney cancer	5.44e-05	0.000188	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—ERBB2—kidney cancer	5.44e-05	0.000188	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—CA9—kidney cancer	5.43e-05	0.000188	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—MTOR—kidney cancer	5.37e-05	0.000186	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—MTOR—kidney cancer	5.37e-05	0.000186	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—IL2—kidney cancer	5.36e-05	0.000186	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—PIK3CA—kidney cancer	5.35e-05	0.000185	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A1—kidney cancer	5.31e-05	0.000184	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—CCND1—kidney cancer	5.23e-05	0.000181	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—JUN—kidney cancer	5.22e-05	0.000181	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—CTNNB1—kidney cancer	5.18e-05	0.000179	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—PTEN—kidney cancer	5.05e-05	0.000175	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—CDKN1B—kidney cancer	5.04e-05	0.000175	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—CDKN1B—kidney cancer	5.04e-05	0.000175	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—IL2—kidney cancer	4.93e-05	0.000171	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—IL2—kidney cancer	4.93e-05	0.000171	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—CCND1—kidney cancer	4.81e-05	0.000167	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—CCND1—kidney cancer	4.81e-05	0.000167	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—JUN—kidney cancer	4.8e-05	0.000166	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—JUN—kidney cancer	4.8e-05	0.000166	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—CTNNB1—kidney cancer	4.76e-05	0.000165	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—CTNNB1—kidney cancer	4.76e-05	0.000165	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—PTEN—kidney cancer	4.64e-05	0.000161	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—PTEN—kidney cancer	4.64e-05	0.000161	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—CRABP1—kidney cancer	4.62e-05	0.00016	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—VEGFA—kidney cancer	4.56e-05	0.000158	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—MAPK3—kidney cancer	4.31e-05	0.000149	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—ITPR2—kidney cancer	4.29e-05	0.000149	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—VEGFA—kidney cancer	4.19e-05	0.000145	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—VEGFA—kidney cancer	4.19e-05	0.000145	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—MYC—kidney cancer	4.19e-05	0.000145	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—MAPK1—kidney cancer	4.1e-05	0.000142	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—MAPK3—kidney cancer	3.97e-05	0.000137	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—MAPK3—kidney cancer	3.97e-05	0.000137	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—POMC—kidney cancer	3.96e-05	0.000137	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—GSTT1—kidney cancer	3.91e-05	0.000136	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—ACHE—kidney cancer	3.91e-05	0.000136	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—KRAS—kidney cancer	3.87e-05	0.000134	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—MYC—kidney cancer	3.86e-05	0.000134	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—MYC—kidney cancer	3.86e-05	0.000134	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—MAPK1—kidney cancer	3.77e-05	0.000131	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—MAPK1—kidney cancer	3.77e-05	0.000131	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—SCARB1—kidney cancer	3.71e-05	0.000128	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PTGS1—kidney cancer	3.67e-05	0.000127	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PSMD7—kidney cancer	3.6e-05	0.000125	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—KRAS—kidney cancer	3.57e-05	0.000123	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—KRAS—kidney cancer	3.57e-05	0.000123	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—PIK3CA—kidney cancer	3.56e-05	0.000123	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—TP53—kidney cancer	3.44e-05	0.000119	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—BCHE—kidney cancer	3.41e-05	0.000118	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—SLC5A5—kidney cancer	3.37e-05	0.000117	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—PIK3CA—kidney cancer	3.28e-05	0.000113	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—PIK3CA—kidney cancer	3.28e-05	0.000113	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—SLC2A1—kidney cancer	3.25e-05	0.000113	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—TP53—kidney cancer	3.17e-05	0.00011	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—TP53—kidney cancer	3.17e-05	0.00011	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	3.16e-05	0.000109	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	2.75e-05	9.53e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—GSTP1—kidney cancer	2.71e-05	9.39e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—ABCB1—kidney cancer	2.57e-05	8.89e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—GSTM1—kidney cancer	2.49e-05	8.63e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—CYP1A1—kidney cancer	2.36e-05	8.18e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	1.94e-05	6.72e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—POMC—kidney cancer	1.76e-05	6.1e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PTGS2—kidney cancer	1.41e-05	4.87e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PTEN—kidney cancer	1.23e-05	4.24e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PIK3CA—kidney cancer	8.65e-06	2.99e-05	CbGpPWpGaD
